Skip to content

Gyre Therapeutics, Inc. GYRE Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

Viking Therapeutics logo
Viking TherapeuticsVKTX
-$4.63M-148%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$3.79M-71.2%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$2.05M-618%
LQD
Liquidia CorporationLQDA
$2.78M+441%
Eli Lilly logo
Eli LillyLLY
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL

Other financials

Income statement

See full
Revenue$22.5M+2.1%
Gross profit$21.3M+0.6%
Operating income-$9.4M-512%
Net income-$8.7M-422%
EPS (diluted)-$0.10

Balance sheet

See full
Cash & equivalents$37.5M+149%
Total debt$823.0K-48.1%
Total equity$101.3M+48.7%
Total assets$162.0M+24.8%

Cash flow

See full
Operating cash flow$3.2M+2,565%
CapEx$178.0K+45.9%
Free cash flow$3.0M+1,296%

Valuation

See full
Market cap$694.58M-4.7%
Enterprise value$657.9M-8.0%
P/S5.9×-1.3×

Profitability

See full
Gross margin95.1%-1.1pp
Operating margin-0.1%-10.4pp
Net margin6.3%+3.3pp
FCF margin2.6%

Returns & leverage

See full
Return on equity8.2%+4.2pp
Debt / equity0.0×
Current ratio4.6×+1.0×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s increase (decrease) in prepaid expense and other assets?
Gyre Therapeutics, Inc. (GYRE) reported increase (decrease) in prepaid expense and other assets of $912K in Q1 2026.
How has Gyre Therapeutics, Inc.'s increase (decrease) in prepaid expense and other assets changed year-over-year?
Gyre Therapeutics, Inc.'s increase (decrease) in prepaid expense and other assets decreased by 83.5% year-over-year, from $5.54M to $912K.
What does increase (decrease) in prepaid expense and other assets mean?
This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.